Navamedic ASA (NAVA) – Financial and Strategic SWOT Analysis Review

Navamedic ASA (NAVA) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
42
Pharmaceuticals and Healthcare
Norway

Navamedic ASA (NAVA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Navamedic ASA (Navamedic), formerly Glucomed AS, is a speciality pharmaceutical products company. It markets and distributes more than 120 products in the Nordic and Benelux markets. The company undertakes the in-licensing and sale of pharmaceuticals and other health care products. Its product portfolio includes a wide range of generics and specialty pharmaceuticals, medical devices, food supplements and other products in the healthcare domain. The company operates its business into three segments, namely, Pharma, Medical Nutrition and Consumer Care. The Pharma segment involves the generics business covering prescription drugs that are sold in pharmacies and hospitals.

Navamedic ASA Key Recent Developments

Feb 27, 2015 Navamedic Announces fourth quarter report 2014
Oct 31, 2014 Navamedic Q3 2014 Results
Aug 22, 2014 Navamedic Q2 2014 results
Aug 22, 2014 Navamedic Announces second quarter 2014 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Navamedic ASA – Key Facts 6
Navamedic ASA – Key Employees 7
Navamedic ASA – Key Employee Biographies 8
Navamedic ASA – Major Products and Services 9
Navamedic ASA – History 10
Navamedic ASA – Company Statement 14
Navamedic ASA – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Navamedic ASA – Business Description 16
Navamedic ASA – Corporate Strategy 17
Navamedic ASA – SWOT Analysis 18
SWOT Analysis – Overview 18
Navamedic ASA – Strengths 18
Strength – Increase in Revenue 18
Strength – Growing Segments 18
Strength – Aspen Pharma and Vitaflo Partnerships 18
Navamedic ASA – Weaknesses 19
Weakness – Decline in Cash Flows 19
Navamedic ASA – Opportunities 20
Opportunity – Product Launches 20
Opportunity – Growth Prospects: Generics Market 20
Opportunity – Changing Demographics 20
Navamedic ASA – Threats 21
Threat – Intense Competition 21
Threat – Foreign Exchange Risk 21
Threat – Stringent Government Regulations 21
Navamedic ASA – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 29
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 30
Navamedic ASA, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Feb 27, 2015: Navamedic Announces fourth quarter report 2014 32
Oct 31, 2014: Navamedic Q3 2014 Results 33
Aug 22, 2014: Navamedic Q2 2014 results 34
Aug 22, 2014: Navamedic Announces second quarter 2014 financial results 35
Mar 04, 2014: Navamedic expands female care product group 36
Feb 26, 2014: Improved sales and operating result for Navamedic 37
Section 6 – Appendix 38
Methodology 38
Ratio Definitions 38
About GlobalData 42
Contact Us 42
Disclaimer 42



List of Tables
Navamedic ASA, Key Facts 6
Navamedic ASA, Key Employees 7
Navamedic ASA, Key Employee Biographies 8
Navamedic ASA, Major Products and Services 9
Navamedic ASA, History 10
Navamedic ASA, Subsidiaries 15
Navamedic ASA, Key Competitors 22
Navamedic ASA, Ratios based on current share price 23
Navamedic ASA, Annual Ratios 24
Navamedic ASA, Interim Ratios 27
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 29
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 30
Navamedic ASA, Recent Deals Summary 31
Currency Codes 38
Capital Market Ratios 38
Equity Ratios 39
Profitability Ratios 39
Cost Ratios 40
Liquidity Ratios 40
Leverage Ratios 41
Efficiency Ratios 41



List of Figures
Navamedic ASA, Performance Chart (2009 – 2013) 26
Navamedic ASA, Ratio Charts 28
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 29
Navamedic ASA, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 30

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.